Incyte Corp. is a pharmaceutical company headquartered in the United States that focuses on discovering and developing small-molecule drugs. The company has a medium risk rating score of 23.8 and is known for its ESG initiatives. Incyte's lead drug, Jakafi, is used for treating rare blood cancers and graft versus host disease. Additionally, the company offers a range of other drugs for conditions such as rheumatoid arthritis, leukemia, lung cancer, and lymphoma. In 2021, Incyte received approval for its dermatology product, Opzelura, for atopic dermatitis and vitiligo. The company's pipeline includes various oncology and dermatology programs, emphasizing its commitment to ESG principles.